Impact of potassium supplementation on thiazide diuretic-induced abnormalities of glucose and uric acid metabolisms

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006003

Enrollment

Unknown

Registered

2015-03-01

Start date

2015-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

A:indapamide

B:indapamide 1.25mg once a day, KCI 1g, three time a day

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Who has a systolic BP of 140-179 mmHg and/or a diastolic BP of 90-109 mmHg; (2) Form thirty to sixty; Sex not limited; (3) No antihypertensive therapy before and no other drug treatment within 3 months; (4) The patient accept this clinical trial.

Exclusion criteria

Exclusion criteria: (1) secondary hypertension; diabetes mellitus; arthrolithiasis; (2) coronary diseasemyocardial diseases, valvular heart disease; NYHA class II or above; (3) cerebral hemorrhage or cerebral infarction; (4) liver or kidney disease(AST passed 2 times, Cr passed 133umol/L), a history of persistent chronic hepatitis; (5) pregnancy, lactation,prolonged of contraceptives; (6) allergic constitution, allergic to the trial drug; (7) the pateint who is unsuited this trial judged by the researcher.

Design outcomes

Primary

Measure	Time frame
FPG;OGTT2hPG;OGTT2hINS;HbA1c;serum potassium;uric acid;	—

Countries

China

Contacts

Public ContactJian-liang Zhang

Cardiology department, The Second Military Medical College, Changhai Hospital, Shanghai

zhang_jianl@sina.com+86 13916913437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026